Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
First Claim
Patent Images
1. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a biologically active 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt thereof in combination or alternation with interferon to a host in need thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.
-
Citations
25 Claims
-
1. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a biologically active 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt thereof in combination or alternation with interferon to a host in need thereof. - View Dependent Claims (25)
- -deoxy-β
-
2. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside of the formula;
or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and
BASE is a purine or pyrimidine base that may optionally be substituted;
in combination or alternation with interferon to a host in need thereof. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
Y is OR3, NR3R4 or SR3; and
X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, halogen, OR5, NR5NR6 or SR5; and
R3, R4, R5 and R6 are independently H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.
- -deoxy-β
-
4. The method of claim 3, wherein the 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside is a β
-L-2′
-deoxyadenosine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl, or a stabilized phosphate derivative.
- -deoxy-β
-
5. The method of claim 4, wherein R1 is hydrogen.
-
6. The method of claim 5, wherein R1 is acyl.
-
7. The method of claim 6, wherein the acyl is derived from an amino acid.
-
8. The method of claim 7, wherein the amino acid is valine.
-
9. The method of claim 3, wherein the 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside is a β
-L-2′
-deoxyguanosine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl, or a stabilized phosphate derivative.
- -deoxy-β
-
10. The method of claim 3, wherein the 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside is a β
-L-2′
-deoxyinosine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl, or a stabilized phosphate derivative.
- -deoxy-β
-
11. The method of claim 2, wherein the 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside is a β
-L-2′
-deoxypyrimidine of the formula;
or a pharmaceutically acceptable salt or prodrug thereof, wherein R1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative;
Y is OR3, NR3R4 or SR3; and
X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, halogen, OR5, NR5NR6 or SR5; and
R3, R4, R5 and R6 are independently H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative.
- -deoxy-β
-
12. The method of claim 11, wherein the 2′
- -deoxy-β
-L-erythro-pentofuranonucleoside is a β
-L-2′
-deoxyuridine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl, or a stabilized phosphate derivative.
- -deoxy-β
-
13. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a β
- -L-2′
-deoxycytidine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl, or a stabilized phosphate derivative;
in combination or alternation with interferon to a host in need thereof. - View Dependent Claims (14, 15, 16, 17)
- -L-2′
-
18. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a β
- -L-thymidine of the formula;
or pharmaceutically acceptable salt thereof, wherein R1 is H, mono, di or triphosphate, acyl, alkyl or a stabilized phosphate derivative;
in combination or alternation with interferon to a host in need thereof. - View Dependent Claims (19, 20, 21, 22)
- -L-thymidine of the formula;
-
23. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a β
- -L-2′
-deoxycytidine of the formula;
or pharmaceutically acceptable salt thereof, in combination or alternation with interferon.
- -L-2′
-
24. A method for treating a host infected with hepatitis D virus comprising administering an effective hepatitis D treatment amount of a β
- -L-thymidine of the formula;
or pharmaceutically acceptable salt thereof, in combination or alternation with interferon.
- -L-thymidine of the formula;
Specification